Roivant Sciences Ltd. — Form 10-Q Summary
Business context and reporting period
This filing reports the quarter ended June 30, 2021 (Roivant’s fiscal 2022 first quarter), not 2020 Q1 as indicated in the request metadata. The statements are unaudited. Roivant builds biotechnology and healthcare technology subsidiaries (“Vants”); it had not generated revenue from product sales. The filing discusses a proposed business combination with Montes Archimedes Acquisition Corp. (MAAC).
Key financial metrics
| Metric | Quarter ended June 30, 2021 | Comparable 2020 quarter |
|---|---|---|
| Revenue | $7.7 million | $1.6 million |
| Research and development expense | $78.6 million | $58.7 million |
| General and administrative expense | $82.8 million | $57.1 million |
| Loss from operations | $154.4 million | $114.5 million |
| Net loss | $101.1 million | $8.0 million |
| Net loss attributable to Roivant | $82.2 million; $0.37 per share | $3.2 million; $0.02 per share |
| Cash used in operating activities | $141.2 million | $111.2 million |
| Cash and cash equivalents at quarter-end | $1.997 billion | Not provided here |
| Total debt, net | $186.4 million | Not provided here |
At June 30, 2021, total assets were $2.455 billion, current assets $2.058 billion and current liabilities $209.2 million. Cash, cash equivalents and restricted cash totaled $2.008 billion. The company reported a $2.001 billion accumulated deficit. No operating margin was disclosed; the operating loss was approximately 20 times quarterly revenue. Long-term debt was reported with no current portion.
Changes versus the prior comparable quarter
- Revenue increased $6.2 million, primarily from recognition of upfront license payments; it remained immaterial relative to operating costs.
- R&D expense rose $19.9 million, mainly from higher personnel costs, including resources added after acquisitions. Gimsilumab spending was lower than in 2020, when costs included a COVID-19 ARDS study.
- G&A expense rose $25.6 million, reflecting higher professional and transaction fees, personnel costs and share-based compensation, including costs related to preparing to operate as a public company.
- Operating cash use increased $30.0 million. Cash and restricted cash declined $133.3 million during the quarter, versus an increase of $44.3 million in the prior-year period.
- Net loss increased substantially, but comparisons are affected by large non-operating items in both periods: the 2021 quarter included a $66.5 million gain on termination of Sumitomo options; the 2020 quarter included an $86.5 million gain on Datavant deconsolidation and a $41.1 million fair-value gain on investments. Investment fair-value changes were an $8.6 million loss in 2021.
Outlook, commentary, risks and unusual items
- Management said existing cash was expected to fund committed operating expenses and capital expenditure requirements for at least 12 months from issuance of the statements. It also expects further losses and says additional capital may be needed; financing may not be available on acceptable terms.
- Management expects R&D and G&A expenses to increase as programs advance, discovery activities expand, and public-company costs rise. No numerical earnings or revenue guidance was provided.
- Dermavant’s $40 million secured facility carries 10% annual interest and a five-year maturity. Roivant reported $195.2 million principal debt, including Dermavant’s NovaQuest financing measured at fair value. A separate $160 million tapinarof revenue-interest financing was committed subject to FDA approval; funding had not occurred by quarter-end.
- The Sumitomo transaction terminated options over certain Vants and transferred specified regional product rights. The $5 million cash payment was received in August 2021; the reported quarter included the $66.5 million accounting gain. The former $75 million indemnification escrow was released to Roivant in June 2021.
- Subsequent to quarter-end, Roivant received approximately $320 million cash and a minority stake following Datavant’s July 2021 merger with CIOX. Proteovant received a second $100 million SK investment payment in July. In August, Roivant invested $200 million in Immunovant; in August and September, Dermavant’s tapinarof NDA was accepted for filing and a Phase 3 atopic dermatitis trial began. These events are not quarter-end cash or operating results.
- Key development risks include uncertain clinical and regulatory outcomes, manufacturing and intellectual-property exposure, and COVID-19-related trial disruption. Immunovant had paused global dosing of IMVT-1401 in February 2021 after elevated cholesterol and LDL levels; the ASCEND GO-2 trial was terminated with inconclusive efficacy results. The filing describes further regulatory discussions as planned.
- COVID-19 had delayed some development timelines but had not caused a material financial impact through the reporting date, according to management. The company reported no material off-balance-sheet arrangements and no probable, estimable material legal loss. Disclosure controls were assessed as effective at quarter-end.
Important facts for investors to verify
- Confirm the quarter and fiscal-year period: the filing covers the three months ended June 30, 2021, despite the request’s “2020 Q1” label.
- Track quarterly cash burn, cash runway assumptions and future financing needs; the 12-month liquidity statement is based on forecasts that may prove inaccurate.
- Assess the effect of nonrecurring gains and investment fair-value movements when comparing reported losses across periods.
- Verify the progress and outcomes of tapinarof regulatory review and trials, and the status of IMVT-1401 after its safety-related pause and inconclusive terminated trial.
- Monitor debt terms and contingent obligations, including the NovaQuest milestone structure and the conditional tapinarof revenue-interest funding.
- Review the completion and financial effects of the MAAC business combination and post-quarter transactions; the filing’s quarter-end financial statements do not include their subsequent cash proceeds or investment.